Personalized Need-focused Single Session Intervention

Description

This is a two-site randomized controlled trial, with two goals. First, the investigators aim to demonstrate that single-session interventions for mild-to-moderate anxiety and depression can generate statistically significant symptom change as a main effect across control and experimental (i.e. personalized) conditions. Second, the investigators hope to establish the additional incremental efficacy of personalization via person-specific intensive longitudinal data collection and analysis.

Conditions

Depression and/or Anxiety in the Mild-to-moderate Range

Study Overview

Study Details

Study overview

This is a two-site randomized controlled trial, with two goals. First, the investigators aim to demonstrate that single-session interventions for mild-to-moderate anxiety and depression can generate statistically significant symptom change as a main effect across control and experimental (i.e. personalized) conditions. Second, the investigators hope to establish the additional incremental efficacy of personalization via person-specific intensive longitudinal data collection and analysis.

Randomized Controlled Trial for Personalized Need-focused Single-Session Interventions

Personalized Need-focused Single Session Intervention

Condition
Depression and/or Anxiety in the Mild-to-moderate Range
Intervention / Treatment

-

Contacts and Locations

Berkeley

University of California, Berkeley, Berkeley, California, United States, 94720

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Bar-Ilan University, Israel,

    Study Record Dates

    2024-09-30